The Motley Fool

Why GlaxoSmithKline plc shares could be the buy of the decade

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

GlaxoSmithKline (LSE: GSK) is the UK’s biggest pharmaceuticals group and the FTSE 100‘s number-five-ranked stock. It’s a popular pick for many investors, due to its blue-chip status, global reach and diversified business. In addition to its core pharmaceuticals division, it has a consumer healthcare business and vaccines and HIV treatments divisions.

Currently, across the heavyweights of 10 industries, Glaxo is the best-value stock based on its P/E and dividend yield. Could it also be the buy of the decade?

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Outlook

A company doesn’t trade on a P/E as low as 12.3 and sport a yield as high as 6% without the market having some concerns about the outlook for the business. While many investors cherish the group’s diversification, a number of high-profile institutional shareholders and analysts have questioned the returns it’s delivered and will deliver in the future.

The HIV franchise has been a genuine growth success but competition is hotting up. Growth in vaccines has faltered in recent years. The consumer healthcare business has made modest progress but its growth rate and margins have been well below those of its peers. And analysts at Morgan Stanley recently said: “The drugmaker needs to refresh its pharmaceuticals pipeline but capital is constrained by the 80p-per-share dividend, which will consume more than three-quarters of GSK’s free cash flow next year.”

Conglomerate vs breakup

It was largely these concerns that led ace investor Neil Woodford to sell his position in the stock last year after holding it for more than 15 years. He and like-minded institutional investors had impressed upon chief executive Andrew Witty their view that “splitting the group into more focused units would allow dedicated management teams to independently realise the full potential of these businesses.” Their view was heard but repeatedly ignored and with Witty’s successor Emma Walmsley billing herself as a ‘continuity candidate’, Woodford felt “the prospect of a Glaxo breakup now looks more remote than ever.”

However, I believe that if the group continues as a conglomerate, it could still deliver decent returns for shareholders, even if a dividend rethink were required. In this respect, I agree with the Morgan Stanley analysts, who argue that a 50% dividend cut “to fund a compelling growth story” would be worth the short-term pain.

Sum of the parts

I rate Glaxo a ‘buy’ on the prospects of the continuing business — albeit not the buy of the decade — but I also wouldn’t rule out the possibility of a strategic U-turn and an immediately-value-unlocking breakup or partial breakup of the group.

Coincidently, the current share price of 1,350p and market cap of £67bn are almost exactly the same as when Woodford’s team presented a thesis that “the sum of the parts is significantly greater than the whole” back in 2014. This suggested a potential valuation of £100bn or around 2,000p a share. Now, if Glaxo did go down the breakup route and unlock anything like that value, it might just turn out to be the buy of the decade today, at least among the FTSE 100 megacaps.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.